Contact
searchSearch
HMP Global
Login

Multiple Myeloma Specialty Channel

Multiple Myeloma
Specialty Channel
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
Quiz
Pomalidomide-Based Regimen for Multiple Myeloma Treatment
09/19/2025
True or False: For patients with first-relapsed multiple myeloma, the addition of pomalidomide to bortezomib and dexamethasone demonstrated a significantly worse progression-free survival and overall response rate compared with control...
True or False: For patients with first-relapsed multiple myeloma, the addition of pomalidomide to bortezomib and dexamethasone demonstrated a significantly worse progression-free survival and overall response rate compared with control...
True or False: For patients with...
09/19/2025
Oncology
News
Belantamab Mafodotin Shows Real-World Efficacy Among Patients With Heavily Pretreated Multiple Myeloma
09/15/2025
Emily Estrada
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
In a real-world observational...
09/15/2025
Oncology
Faith Davies, MD
Conference Coverage
Determining When Treatment for Patients With High-Risk Smoldering MM is Appropriate
08/06/2025
Faith E. Davies, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Faith Davies, MD, participated in a debate on the benefits of treating patients with high-risk smoldering multiple myeloma.
At the 2025 Great Debates in Hematologic Malignancies meeting, Faith Davies, MD, participated in a debate on the benefits of treating patients with high-risk smoldering multiple myeloma.
At the 2025 Great Debates in...
08/06/2025
Oncology
Peter Voorhees, MD
Conference Coverage
Strategy for Treatment of High-Risk Smoldering Myeloma Prior to Disease Progression
08/06/2025
Peter Voorhees, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Peter Voorhees, MD, discusses strategies for treating patients with high-risk smoldering multiple myeloma to prevent or slow disease progression, citing findings from the phase 3...
At the 2025 Great Debates in Hematologic Malignancies meeting, Peter Voorhees, MD, discusses strategies for treating patients with high-risk smoldering multiple myeloma to prevent or slow disease progression, citing findings from the phase 3...
At the 2025 Great Debates in...
08/06/2025
Oncology
Quiz
Venetoclax Plus Bortezomib and Dexamethasone Therapy for R/R MM
08/04/2025
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical...
08/04/2025
Oncology
News
AQUILA Phase 3 Trial Leads to European Commission Approval of Daratumumab for Smoldering Multiple Myeloma
07/24/2025
Emily Estrada
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
For patients with high-risk...
07/24/2025
Oncology
Quiz
Belantamab Mafodotin Combination for R/R Multiple Myeloma
07/17/2025
In the DREAMM-8 trial, patients with multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone demonstrated what median PFS compared to those receiving pomalidomide, bortezomib, and dexamethasone?
In the DREAMM-8 trial, patients with multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone demonstrated what median PFS compared to those receiving pomalidomide, bortezomib, and dexamethasone?
In the DREAMM-8 trial, patients...
07/17/2025
Oncology
News
Pomalidomide-Based Regimen Shows Improved Overall Response Rate and Progression-Free Survival for Patients With MM in First Relapse
07/17/2025
Emily Estrada
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
A regimen of bortezomib and...
07/17/2025
Oncology
News
Venetoclax Plus Bortezomib and Dexamethasone Combination Therapy Demonstrates Inferior Overall Survival for Patients With R/R MM
07/09/2025
Emily Estrada
Venetoclax plus bortezomib and dexamethasone treatment demonstrated inferior overall survival and superior progression-free survival for patients with relapsed/refractory multiple myeloma compared to patients treated with placebo.
Venetoclax plus bortezomib and dexamethasone treatment demonstrated inferior overall survival and superior progression-free survival for patients with relapsed/refractory multiple myeloma compared to patients treated with placebo.
Venetoclax plus bortezomib and...
07/09/2025
Oncology
News
Quadruplet Regimen of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone Shows Efficacy for Newly Diagnosed MM
07/08/2025
Emily Estrada
A quadruplet therapy of subcutaneous daratumumab in addition to bortezomib, thalidomide, and dexamethasone demonstrated promising efficacy and safety among patients with newly diagnosed multiple myeloma.
A quadruplet therapy of subcutaneous daratumumab in addition to bortezomib, thalidomide, and dexamethasone demonstrated promising efficacy and safety among patients with newly diagnosed multiple myeloma.
A quadruplet therapy of...
07/08/2025
Oncology

News

News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
Belantamab Mafodotin Shows Real-World Efficacy Among Patients With Heavily Pretreated Multiple Myeloma
09/15/2025
Emily Estrada
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
In a real-world observational...
09/15/2025
Oncology
Faith Davies, MD
Conference Coverage
Determining When Treatment for Patients With High-Risk Smoldering MM is Appropriate
08/06/2025
Faith E. Davies, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Faith Davies, MD, participated in a debate on the benefits of treating patients with high-risk smoldering multiple myeloma.
At the 2025 Great Debates in Hematologic Malignancies meeting, Faith Davies, MD, participated in a debate on the benefits of treating patients with high-risk smoldering multiple myeloma.
At the 2025 Great Debates in...
08/06/2025
Oncology
Peter Voorhees, MD
Conference Coverage
Strategy for Treatment of High-Risk Smoldering Myeloma Prior to Disease Progression
08/06/2025
Peter Voorhees, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Peter Voorhees, MD, discusses strategies for treating patients with high-risk smoldering multiple myeloma to prevent or slow disease progression, citing findings from the phase 3...
At the 2025 Great Debates in Hematologic Malignancies meeting, Peter Voorhees, MD, discusses strategies for treating patients with high-risk smoldering multiple myeloma to prevent or slow disease progression, citing findings from the phase 3...
At the 2025 Great Debates in...
08/06/2025
Oncology
News
AQUILA Phase 3 Trial Leads to European Commission Approval of Daratumumab for Smoldering Multiple Myeloma
07/24/2025
Emily Estrada
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
For patients with high-risk...
07/24/2025
Oncology
News
Pomalidomide-Based Regimen Shows Improved Overall Response Rate and Progression-Free Survival for Patients With MM in First Relapse
07/17/2025
Emily Estrada
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
A regimen of bortezomib and...
07/17/2025
Oncology
News
Venetoclax Plus Bortezomib and Dexamethasone Combination Therapy Demonstrates Inferior Overall Survival for Patients With R/R MM
07/09/2025
Emily Estrada
Venetoclax plus bortezomib and dexamethasone treatment demonstrated inferior overall survival and superior progression-free survival for patients with relapsed/refractory multiple myeloma compared to patients treated with placebo.
Venetoclax plus bortezomib and dexamethasone treatment demonstrated inferior overall survival and superior progression-free survival for patients with relapsed/refractory multiple myeloma compared to patients treated with placebo.
Venetoclax plus bortezomib and...
07/09/2025
Oncology
News
Quadruplet Regimen of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone Shows Efficacy for Newly Diagnosed MM
07/08/2025
Emily Estrada
A quadruplet therapy of subcutaneous daratumumab in addition to bortezomib, thalidomide, and dexamethasone demonstrated promising efficacy and safety among patients with newly diagnosed multiple myeloma.
A quadruplet therapy of subcutaneous daratumumab in addition to bortezomib, thalidomide, and dexamethasone demonstrated promising efficacy and safety among patients with newly diagnosed multiple myeloma.
A quadruplet therapy of...
07/08/2025
Oncology
Conference Coverage
Chromosome 1q Abnormalities Associated With Worse Survival Outcomes Among Patients With Newly Diagnosed Multiple Myeloma
06/12/2025
Emily Estrada
Among patients with newly diagnosed multiple myeloma, abnormalities of chromosome 1q were associated with inferior survival outcomes and other high-risk cytogenetic feature, according to data presented at the 2025 ASCO Annual Meeting.
Among patients with newly diagnosed multiple myeloma, abnormalities of chromosome 1q were associated with inferior survival outcomes and other high-risk cytogenetic feature, according to data presented at the 2025 ASCO Annual Meeting.
Among patients with newly...
06/12/2025
Oncology
Conference Coverage
Belantamab Monotherapy Demonstrates Safety and Durable Responses for Heavily Pretreated R/R MM: Results From DREAMM-20
06/05/2025
Emily Estrada
According to interim results from the DREAMM-20 trial, belantamab monotherapy demonstrates safety and efficacy for heavily pretreated patients with relapsed/refractory multiple myeloma.
According to interim results from the DREAMM-20 trial, belantamab monotherapy demonstrates safety and efficacy for heavily pretreated patients with relapsed/refractory multiple myeloma.
According to interim results...
06/05/2025
Oncology

Interactive Features

Quiz
Pomalidomide-Based Regimen for Multiple Myeloma Treatment
09/19/2025
True or False: For patients with first-relapsed multiple myeloma, the addition of pomalidomide to bortezomib and dexamethasone demonstrated a significantly worse progression-free survival and overall response rate compared with control...
True or False: For patients with first-relapsed multiple myeloma, the addition of pomalidomide to bortezomib and dexamethasone demonstrated a significantly worse progression-free survival and overall response rate compared with control...
True or False: For patients with...
09/19/2025
Oncology
Quiz
Venetoclax Plus Bortezomib and Dexamethasone Therapy for R/R MM
08/04/2025
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical...
08/04/2025
Oncology
Quiz
Belantamab Mafodotin Combination for R/R Multiple Myeloma
07/17/2025
In the DREAMM-8 trial, patients with multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone demonstrated what median PFS compared to those receiving pomalidomide, bortezomib, and dexamethasone?
In the DREAMM-8 trial, patients with multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone demonstrated what median PFS compared to those receiving pomalidomide, bortezomib, and dexamethasone?
In the DREAMM-8 trial, patients...
07/17/2025
Oncology
Quiz
Triplet Regimen for Relapsed/Refractory Multiple Myeloma
06/16/2025
What was the most common grade ≥ 3 adverse event associated with a weekly triplet regimen of carfilzomib, cyclophosphamide, and dexamethasone for patients with relapsed/refractory multiple myeloma?
What was the most common grade ≥ 3 adverse event associated with a weekly triplet regimen of carfilzomib, cyclophosphamide, and dexamethasone for patients with relapsed/refractory multiple myeloma?
What was the most common grade ≥...
06/16/2025
Oncology
Quiz
Anti-GPRC5D CAR T-Cell Therapy for Relapsed/Refractory MM
05/01/2025
According to a systematic review and meta-analysis, what proportion of patients with MM treated with anti-GPRC5D CAR T-cell therapy achieved complete response?
According to a systematic review and meta-analysis, what proportion of patients with MM treated with anti-GPRC5D CAR T-cell therapy achieved complete response?
According to a systematic review...
05/01/2025
Oncology
Quiz
GPRC5D-Targeted CAR T-Cell Therapy for Multiple Myeloma
04/02/2025
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported...
04/02/2025
Oncology
Quiz
Weekly Combination Therapy for Patients With R/R Multiple Myeloma
07/11/2024
07/11/2024
Oncology
Quiz
Treating R/R Multiple Myeloma With Fractionated BCMA-Directed CAR T-Cell Therapy ARI0002h
01/30/2024
According to an interim analysis from the CARTBCMA-HCB-01 pilot study, ARI0002h, a BCMA-targeted CAR T-cell therapy developed within the academic setting, demonstrated encouraging responses when administered in a fractionated manner with a...
According to an interim analysis from the CARTBCMA-HCB-01 pilot study, ARI0002h, a BCMA-targeted CAR T-cell therapy developed within the academic setting, demonstrated encouraging responses when administered in a fractionated manner with a...
According to an interim analysis...
01/30/2024
Oncology
Quiz
Mezigdomide Plus Dexamethasone Oral Combination for Patients With Heavily Pretreated R/R MM
01/19/2024
True or False: The oral combination of mezigdomide plus dexamethasone demonstrated promising efficacy among patients with heavily pretreated, relapsed/refractory (R/R) multiple myeloma (MM), according to findings from a phase 1/2 study.
True or False: The oral combination of mezigdomide plus dexamethasone demonstrated promising efficacy among patients with heavily pretreated, relapsed/refractory (R/R) multiple myeloma (MM), according to findings from a phase 1/2 study.
True or False: The oral...
01/19/2024
Oncology
Quiz
Quiz: Ciltacabtagene Autoleucel CAR T-Cell Therapy for Patients With R/R Multiple Myeloma With Prior BCMA-Targeting Therapy
04/18/2023
In a study assessing the efficacy and safety of ciltacabtagene autoleucel CAR-T-cell therapy among patients with R/R multiple myeloma who had been previously exposed to noncellular anti-B-cell maturation antigen therapies, what was the...
In a study assessing the efficacy and safety of ciltacabtagene autoleucel CAR-T-cell therapy among patients with R/R multiple myeloma who had been previously exposed to noncellular anti-B-cell maturation antigen therapies, what was the...
In a study assessing the...
04/18/2023
Oncology

Recent News

News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
Belantamab Mafodotin Shows Real-World Efficacy Among Patients With Heavily Pretreated Multiple Myeloma
09/15/2025
Emily Estrada
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
In a real-world observational...
09/15/2025
Oncology
News
AQUILA Phase 3 Trial Leads to European Commission Approval of Daratumumab for Smoldering Multiple Myeloma
07/24/2025
Emily Estrada
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
For patients with high-risk...
07/24/2025
Oncology
News
Pomalidomide-Based Regimen Shows Improved Overall Response Rate and Progression-Free Survival for Patients With MM in First Relapse
07/17/2025
Emily Estrada
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
A regimen of bortezomib and...
07/17/2025
Oncology
News
Venetoclax Plus Bortezomib and Dexamethasone Combination Therapy Demonstrates Inferior Overall Survival for Patients With R/R MM
07/09/2025
Emily Estrada
Venetoclax plus bortezomib and dexamethasone treatment demonstrated inferior overall survival and superior progression-free survival for patients with relapsed/refractory multiple myeloma compared to patients treated with placebo.
Venetoclax plus bortezomib and dexamethasone treatment demonstrated inferior overall survival and superior progression-free survival for patients with relapsed/refractory multiple myeloma compared to patients treated with placebo.
Venetoclax plus bortezomib and...
07/09/2025
Oncology
News
Quadruplet Regimen of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone Shows Efficacy for Newly Diagnosed MM
07/08/2025
Emily Estrada
A quadruplet therapy of subcutaneous daratumumab in addition to bortezomib, thalidomide, and dexamethasone demonstrated promising efficacy and safety among patients with newly diagnosed multiple myeloma.
A quadruplet therapy of subcutaneous daratumumab in addition to bortezomib, thalidomide, and dexamethasone demonstrated promising efficacy and safety among patients with newly diagnosed multiple myeloma.
A quadruplet therapy of...
07/08/2025
Oncology
Conference Coverage
Chromosome 1q Abnormalities Associated With Worse Survival Outcomes Among Patients With Newly Diagnosed Multiple Myeloma
06/12/2025
Emily Estrada
Among patients with newly diagnosed multiple myeloma, abnormalities of chromosome 1q were associated with inferior survival outcomes and other high-risk cytogenetic feature, according to data presented at the 2025 ASCO Annual Meeting.
Among patients with newly diagnosed multiple myeloma, abnormalities of chromosome 1q were associated with inferior survival outcomes and other high-risk cytogenetic feature, according to data presented at the 2025 ASCO Annual Meeting.
Among patients with newly...
06/12/2025
Oncology
Conference Coverage
Belantamab Monotherapy Demonstrates Safety and Durable Responses for Heavily Pretreated R/R MM: Results From DREAMM-20
06/05/2025
Emily Estrada
According to interim results from the DREAMM-20 trial, belantamab monotherapy demonstrates safety and efficacy for heavily pretreated patients with relapsed/refractory multiple myeloma.
According to interim results from the DREAMM-20 trial, belantamab monotherapy demonstrates safety and efficacy for heavily pretreated patients with relapsed/refractory multiple myeloma.
According to interim results...
06/05/2025
Oncology
Conference Coverage
Belantamab Mafodotin Combination for R/R Multiple Myeloma Shows PFS Benefit for Patients With High-Risk Cytogenetic Abnormalities
06/05/2025
Emily Estrada
The combination of belantamab mafodotin plus pomalidomide and dexamethasone demonstrated improved survival and response rates compared to pomalidomide plus bortezomib and dexamethasone for patients with R/R MM and high-risk cytogenetic...
The combination of belantamab mafodotin plus pomalidomide and dexamethasone demonstrated improved survival and response rates compared to pomalidomide plus bortezomib and dexamethasone for patients with R/R MM and high-risk cytogenetic...
The combination of belantamab...
06/05/2025
Oncology
News
Circulating Tumor Cell Burden May Help Identify High-Risk Subset of Patients With Multiple Myeloma
05/07/2025
Emily Estrada
The presence of 2% or more circulating tumor cells at time of diagnosis may indicate an ultra-high-risk subset of patients with multiple myeloma, according to a cohort analysis.
The presence of 2% or more circulating tumor cells at time of diagnosis may indicate an ultra-high-risk subset of patients with multiple myeloma, according to a cohort analysis.
The presence of 2% or more...
05/07/2025
Oncology
News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use